5 Key Takeaways

• 1

  Ixekizumab showed faster early skin responses than guselkumab or ustekinumab after secukinumab treatment failure in a real-world cohort.

• 2

  67% of patients switching to ixekizumab achieved PASI 75 at week 12, compared to 28% with guselkumab and 17% with ustekinumab.

• 3

  The study evaluated 59 patients with moderate-to-severe plaque psoriasis who switched biologics due to treatment failure or adverse events.

• 4

  Safety profiles were similar across all treatment groups, with 20% of patients experiencing mild adverse events.

• 5

  Subgroup analyses indicated that treatment history may influence response to biologic switching, though findings were not statistically significant.